Welcome to this issue of IJPN. We are pleased to have an extensive range of original research papers, in addition to a number of case reports, with a strong focus on neonatal topics.

Vasyman et al discuss an emerging therapy for premature babies that aims to ameliorate the problems associated with hyaline membrane disease. There has been little progress in this area since the introduction of steroids and surfactant, and the authors present data from a pilot study using recombinant superoxide dismutase therapy in the early neonatal period.

Parasuraman et al and Vachharajani et al remind us of the potential complications of commonly used devices and therapies. They present cases of iatrogenic problems caused by the use of nasogastric tubes and indomethacin respectively.

The controversy surrounding use of the MMR vaccine in the UK continues, despite the extensive evidence for its safety. Cases of measles infection continues to rise from a previously enviably low rate. The outcome of the serious misconduct proceedings by the GMC against Dr Wakefield and colleagues is awaited. Against this backdrop, the original research paper from Adetunji et al starkly illustrates the problems caused by preventable infectious diseases in under-resourced settings, where full coverage by a measles vaccination programme is hard to achieve.